^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zevorcabtagene autoleucel (CT053)

    i
    Associations
    News

    Trials

    Company:
    CARsgen, Huadong Medicine
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors (NCT03302403)
    Phase N/A
    Kang YU
    Active, not recruiting
    Last update posted :
    10/08/2020
    Initiation :
    12/29/2017
    Primary completion :
    12/12/2020
    Completion :
    12/12/2023
    CLDN18 • GPC3
    |
    CD19 positive • GPC3 positive
    |
    cyclophosphamide • fludarabine IV • satricabtagene autoleucel (CT041) • CT011 • CT0180 • CT032 • cyclophosphamide intravenous • zevorcabtagene autoleucel (CT053)